QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
ImmunityBio, Inc.
ImmunityBio, Inc.
Boehringer Ingelheim
Bristol-Myers Squibb
Bristol-Myers Squibb
NextCure, Inc.
NanOlogy, LLC
Eli Lilly and Company
iOMEDICO AG
Peregrine Pharmaceuticals
Hoffmann-La Roche
Hoffmann-La Roche
Daiichi Sankyo
AmpliMed Corporation
Pfizer
Pfizer
GlaxoSmithKline
GlaxoSmithKline
Arog Pharmaceuticals, Inc.